Celltrion Biosimilar Package Is Strong, But How Many Indications Will It Get?
This article was originally published in The Pink Sheet Daily
Executive Summary
Like Zarxio before it, Inflectra is coming before an advisory committee having received a glowing review from FDA staff; the key question seems to be how many of Remicade's indications will it be able to extrapolate.